New Expansion at Alderley Park

An expansion planned at the UK’s Alderley Park will result in a new facility for the drug research firm Sygnature Discovery which will double their drug metabolism and pharmacokinetics (DMPK) department.

The expansion will be carried out at both Sygnature sites: Alderley Park and Nottingham, England. Within the expansion, the firm plans on carrying out a sustained recruitment programme.

Chief operating officer Dr. Jonathan Williams said “The North West has a wealth of expertise in the field of DMPK and as Alderley Park is home to the UK’s largest life science campus we wanted to align our growth with theirs”.

Leave a Reply

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.